Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 18/20 | 0.68 |
| ▸ | FBP1 | P09467 | 2/20 | 0.60 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.60 |
| ▸ | AURKA | O14965 | 1/20 | 0.60 |
| ▸ | INSR | P06213 | 1/20 | 0.60 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.60 |
| ▸ | FLT4 | P35916 | 1/20 | 0.60 |
| ▸ | KDR | P35968 | 1/20 | 0.60 |
| ▸ | CLK1 | P49759 | 1/20 | 0.60 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.60 |
| ▸ | TEK | Q02763 | 1/20 | 0.60 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.60 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30294136 | 1.00 | EGFR (0.68) | EGFRFBP1ERBB2AURKAINSR | |
| Hydrochloric Acid SCHEMBL8314953 | 0.99 | EGFR (0.67) | EGFRFBP1ERBB2AURKAINSR | |
| SCHEMBL25241 | 0.93 | EGFR (0.63) | EGFRFBP1ERBB2AURKAINSR | |
| SCHEMBL30237488 | 0.93 | EGFR (0.63) | EGFRFBP1ERBB2AURKAINSR | |
| SCHEMBL29615011 | 0.93 | EGFR (0.63) | EGFRFBP1ERBB2AURKAINSR | |
| Hydrochloric Acid SCHEMBL4780920 | 0.92 | EGFR (0.62) | EGFRFBP1ERBB2AURKAINSR | |
| SCHEMBL20305667 | 0.90 | EGFR (0.60) | EGFRFBP1ERBB2AURKAINSR | |
| SCHEMBL18862887 | 0.90 | EGFR (0.60) | EGFRFBP1ERBB2AURKAINSR | |
| SCHEMBL3246075 | 0.90 | EGFR (0.61) | EGFRFBP1ERBB2AURKAINSR | |
| SCHEMBL30113246 | 0.90 | EGFR (0.61) | EGFRFBP1ERBB2AURKAINSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107674059-B | Benzaheteroaromatic ring compound and preparation method and application thereof | 中国药科大学 | 2020-04-14 | — | — | CN | disclosed |
| CN-107216317-B | Preparation method of afatinib intermediate | 上海医药工业研究院 | 2020-04-07 | — | — | CN | disclosed |
| CN-103382182-A | Phenylurea coupling quinazoline compound, and preparation method, pharmaceutical composition and pharmaceutical use thereof | UNIV HEBEI MEDICAL | 2013-11-06 | — | — | CN | disclosed |
| EP-1981863-B1 | PROCESS FOR PREPARING AMINOCROTONYLAMINO-SUBSTITUTED QUINAZOLINE DERIVATIVES | BOEHRINGER INGELHEIM INT (DE) | 2012-10-10 | — | — | EP | disclosed |
| US-8188274-B2 | Process for preparing aminocrotonylamino-substituted quinazoline derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-29 | — | — | US | disclosed |
| US-8067593-B2 | Process for preparing aminocrotonylamino-substituted quinazoline derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-29 | — | — | US | disclosed |
| US-20110207929-A1 | Process for preparing aminocrotonylamino-substituted quinazoline derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-25 | — | — | US | disclosed |
| US-20110207932-A1 | Process for preparing aminocrotonylamino-substituted quinazoline derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-25 | — | — | US | disclosed |
| US-7960546-B2 | Process for preparing aminocrotonylamino-substituted quinazoline derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-06-14 | — | — | US | disclosed |
| EP-1369418-B1 | QUINAZOLINE DERIVATIVES | MITSUBISHI TANABE PHARMA CORP (JP) | 2010-07-28 | — | — | EP | disclosed |
| US-7294629-B2 | Quinazoline derivatives | MITSUBISHI PHARMA CORPORATION (JP) | 2007-11-13 | — | — | US | disclosed |
| WO-2007085638-A1 | PROCESS FOR PREPARING AMINOCROTONYLAMINO-SUBSTITUTED QUINAZOLINE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-08-02 | — | — | WO | disclosed |
| CN-1264824-C | Quinazoline derivatives | MITSUBISHI PHARMA CORP (JP) | 2006-07-19 | — | — | CN | disclosed |
| US-20040116422-A1 | Quinazoline derivatives | MITSUBISHI PHARMA CORPORATION (JP) | 2004-06-17 | — | — | US | disclosed |
| CN-1492860-A | Quinazoline derivatives | ������ҩ��ʽ���� | 2004-04-28 | — | — | CN | disclosed |
| EP-1369418-A1 | QUINAZOLINE DERIVATIVES | Mitsubishi Pharma Corporation (JP) | 2003-12-10 | — | — | EP | disclosed |
| US-5955464-A | USE OF THE RECEPTOR TYROSINE KINASE INHIBITORY PROPERTIES OF THE COMPOUNDS IN THE TREATMENT OF PROLIFERATIVE DISEASE SUCH AS CANCER | ZENECA LIMITED (GB) | 1999-09-21 | — | — | US | disclosed |
| EP-0794953-B1 | QUINAZOLINE DERIVATIVES | ZENECA LTD (GB) | 1999-05-06 | — | — | EP | disclosed |
| EP-0794953-A1 | QUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1997-09-17 | — | — | EP | disclosed |
| WO-1996016960-A1 | QUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1996-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207932-A1 | Process for preparing aminocrotonylamino-substituted quinazoline derivatives | EGFR, CNKSR1, ERBB2 | EGFR 1/4885FBP1 2368/4885ERBB2 3/4885 |
| US-20110207929-A1 | Process for preparing aminocrotonylamino-substituted quinazoline derivatives | EGFR, CNKSR1, ERBB2 | EGFR 1/4885FBP1 2368/4885ERBB2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.